- Home
- SABS vs RLMD Comparison
SABS vs RLMD Comparison
Compare SABS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- RLMD
- Stock Information
- Founded
- SABS 2014
- RLMD 2004
- Country
- SABS United States
- RLMD United States
- Employees
- SABS N/A
- RLMD N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SABS Health Care
- RLMD Health Care
- Exchange
- SABS Nasdaq
- RLMD Nasdaq
- Market Cap
- SABS 11.4M
- RLMD 11.5M
- IPO Year
- SABS N/A
- RLMD N/A
- Fundamental
- Price
- SABS $1.37
- RLMD $0.69
- Analyst Decision
- SABS Strong Buy
- RLMD Hold
- Analyst Count
- SABS 5
- RLMD 4
- Target Price
- SABS $11.40
- RLMD $4.25
- AVG Volume (30 Days)
- SABS 25.6K
- RLMD 2.1M
- Earning Date
- SABS 05-19-2025
- RLMD 05-07-2025
- Dividend Yield
- SABS N/A
- RLMD N/A
- EPS Growth
- SABS N/A
- RLMD N/A
- EPS
- SABS N/A
- RLMD N/A
- Revenue
- SABS $1,322,410.00
- RLMD N/A
- Revenue This Year
- SABS N/A
- RLMD N/A
- Revenue Next Year
- SABS $50.00
- RLMD N/A
- P/E Ratio
- SABS N/A
- RLMD N/A
- Revenue Growth
- SABS N/A
- RLMD N/A
- 52 Week Low
- SABS $1.00
- RLMD $0.24
- 52 Week High
- SABS $5.01
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- SABS 46.90
- RLMD 87.66
- Support Level
- SABS $1.30
- RLMD $0.27
- Resistance Level
- SABS $1.49
- RLMD $0.33
- Average True Range (ATR)
- SABS 0.13
- RLMD 0.06
- MACD
- SABS 0.04
- RLMD 0.03
- Stochastic Oscillator
- SABS 75.51
- RLMD 97.81
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.